Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley Fever in adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

BACKGROUND: Rift Valley Fever (RVF) is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use. We evaluated the safety and immunogenicity of a non-replicating simian adenovirus (ChAdOx1)-vectored RVF vaccin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Infect Dis
Asıl Yazarlar: Jenkin, Daniel, Wright, Daniel, Folegatti, Pedro M., Platt, Abigail, Poulton, Ian, Lawrie, Alison, Tran, Nguyen, Boyd, Amy, Turner, Cheryl, Gitonga, John N., Karanja, Henry K., Mugo, Daisy, Ewer, Katie J., Bowden, Thomas A., Gilbert, Sarah C., Charleston, Bryan, Kaleebu, Pontiano, Hill, Adrian V. S., Warimwe, George M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2023
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614834/
https://ncbi.nlm.nih.gov/pubmed/37060917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(23)00068-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller